Citeline and Norstella Complete Merger to Form $5 Billion Global Pharma Technology Company

With over 1,600 employees worldwide, the new organization is now one of the largest global providers of pharmaceutical intelligence solutions to market.

YARDLEY, Pa., November 1, 2022 /PRNewswire/ — Norstellea global leader providing end-to-end solutions that facilitate access to life-saving therapies for patients, announced the completion of its merger with Quote (formerly Pharma Intelligence), a leader in clinical trial intelligence.

At the close of the case, the $5 billion is now one of the largest global providers of pharmaceutical intelligence solutions on the market, with more than 1,600 employees across the five brands that make up Norstella: Assess, MMIT, Panalgo, The Dedham Groupand now Quote.

This merger will allow Norstella to prioritize rapid innovation to help guide life science companies through the drug development process so patients can get to therapies faster.

“We believe patient access begins with identifying unmet needs and does not end until a patient has a therapy in hand,” said Mike GallupNorstella CEO. “As the industry moves towards highly targeted therapies focused on smaller patient populations, our customers need solutions that provide actionable answers to critical business questions to help bring drugs to market faster, helping patients to receive treatment sooner.”

From the clinical discovery process to commercialization, pharmaceutical manufacturers are overwhelmed with data and inundated with questions regarding the application of real-world data, understanding the burden of disease, communicating the clinical effectiveness of a drug, the revelation of an unexpected positive clinical result or the quantification of the consequence of a delayed therapy on the market.

As a combined organization, Norstella’s solutions will enable pharmaceutical industry stakeholders to quickly identify unmet clinical needs, build clinical trials with informed endpoints that support downstream reimbursement decisions, and accurately identify patients eligible for clinical trials. A powerful example of this is Panalgo’s Instant Health Data (IHD) platformwhich can ingest clinical trial and real-world data from Citeline, MMIT policy, patient lab and restriction data, and clinical pathway data and real-world evidence from The Dedham Group, all of which can be leveraged to quickly answer key questions related to patient travel, payer reimbursement, and therapeutic safety and efficacy.

“This union is an opportunity for Citeline and Norstella to advance their shared mission of making therapies accessible to patients who need them,” said Jay Nadlerexecutive chairman of Norstella and Ramsey Hashem, CEO of Citeline. “We feel the urgency to make an impact, and we believe we can deliver life-changing innovation for patients.”

Gallup added, “A key philosophy at Norstella is to innovate in partnership with our customers; we will continue to ask our customers where the gap is and how we can close it. Together, we aim to create a health market that is more innovative and accessible to everyone.”

About Norstella

At Norstella, our mission is simple: to help patients access lifesaving therapies. Norstella is made up of several leading organizations – Citeline, Evaluate, MMIT, Panalgo and The Dedham Group – which have come together to offer a full range of pharmaceutical consulting services and solutions. As a single organization, Norstella provides life science customers with the right tools and expertise to navigate the complexities at every stage of the drug development lifecycle, from pipeline to patient. For more information, visit Norstelle and follow LinkedIn.

About Citeline

Citeline (formerly Pharma Intelligence) powers a comprehensive suite of complementary business intelligence offerings to meet the ever-changing needs of life science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-centric solutions and services provide and analyze the data used to make clinical, business and regulatory decisions and create real-world growth opportunities.

Our global teams of analysts, journalists and consultants keep the pulse of the pharmaceutical, biomedical and medical technology industries, covering it all with expert information: key diseases, clinical trials, R&D and drug approvals, market forecasts and more. For more information on one of the world’s most trusted life science partners, visit Quote.

Media Contacts

Melody Udell | Director, Communications
+1 312-618-5968 | [email protected]

Blair Dawson | Vice President, Communications and Employee Engagement
+1 919-413-4616 | [email protected]